Lamivudine, Zidovudine Articles

FDA denies Citizen Petition on generic Combivir 180-day exclusivity “First Applicant” issue

3 June 2011

Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil

12 January 2010

FDA panel OKs Pfizer’s Selzentry for broader us in HIV naive patients, but drug criticized for its cost

12 October 2009

GlaxoSmithKline and Pfizer merge HIV interests into new JV company

17 April 2009

Less side effects with switch from Combivir to Truvada

5 November 2007

Truvada/Sustiva cuts viral load vs Combivir/Sustiva

6 August 2007

GlaxoSmithKline in deal to supply HIV/AIDS drugs to Russia

25 September 2006

Atripla approved by FDA for use in HIV-1 therapy

17 July 2006

FDA adds new AE data on label of Gilead's Truvada and Viread

13 March 2006

Mixed data from S-P's vicriviroc in HIV study

20 February 2006

Good efficacy for Gilead Sci's ARV combo

30 January 2006

GSK says combination HIV therapy increases treatment adherence

12 December 2005

WHO, US FDA to share generic HIV/AIDS Rx data

22 August 2005

Aurobindo gets tentative appro for generic ARV

18 July 2005

US FDA acts against Indian generics firms, and African states reject its approvals

27 June 2005

More US FDA HIV/AIDS drug approvals "soon"

14 March 2005

GSK rebrands HIV/ AIDS drugs for Africa

28 February 2005

Gilead reports 48-wk data from HIV study

14 February 2005

US FDA OKs first ARV triple therapy for LDCs

31 January 2005

BI and GSK to co-package HIV drugs

19 July 2004

BI and GSK to co-package HIV drugs

19 July 2004

GSK ARVs placed on EU anti-diversion list

3 May 2004

GSK urges Nigeria to use ARV duty waiver

19 April 2004

GSK moves to stop AIDS drug smugglers

5 January 2004

US/S African on-line pharmacy offering cheap HIV/AIDS drugs

8 September 2003

Gilead starts Viread/Emtriva combi study

18 August 2003

Gilead wins US FDA approval for its once-daily HIV therapy Emtriva

14 July 2003

GSK overcomes Augmentin woes, posts strong sales and earnings in 1st quarter

5 May 2003

GSK cuts HIV/AIDS Rx prices to LDCs again

5 May 2003

Activists fire shot at GSK over Trizivir study

17 March 2003

New ARVs

10 February 2003

US HIV/AIDS group continues its court pursuit of GSK in South Africa

3 February 2003

AIDS group demonstrates against GSK

22 July 2002

Protecting pharmaceuticals from counterfeiting; a practical guide

10 June 2002

Kenyan HIV/AIDS drug shortages hit patients

29 April 2002

GlaxoSmithKline 2001 pretax exceeds forecasts

18 February 2002

HIV/AIDS patients "must get drug treatment," says Mandela

3 December 2001

GSK and Shire's three-combo HIV drug Trizivir gets OK from Canada

7 November 2001

GlaxoSmithKline posts strong 3rd-qtr results as Advair continues to blossom

23 October 2001

GlaxoSmithKline in first South African HIV/AIDS generic drugs license deal

9 October 2001

Immune Response cancels Remune trial

3 September 2001

GlaxoSmithKline turnover up 10% as Advair takes off in the USA

24 July 2001

Superior efficacy for Ziagen/Combivir

11 July 2001

BI's tipranavir effective as HIV salvage regimen

10 July 2001

GSK offers extra cut-price drugs to more customers, incl NGOs, employers,

13 June 2001

Burundi signs up for UN HIV/AIDS drug plan

2 May 2001

Mali, Cameroon to get cheap HIV/AIDS drugs

11 April 2001

GSK: "Combivir's price goes no lower"

9 April 2001

GSK "surprise" at SA HIV/AIDS drugs claim

23 February 2001

GlaxoSmithKline starts life in 2001 on a strong financial footing

21 February 2001

Cipla talks with MNCs over HIV drug offer

13 February 2001

Earnings increase 41% at BioChem Pharma

1 February 2001

S Africa OKs generic Diflucan imports

1 December 2000

GW wins FDA approval for Trizivir

16 November 2000

HIV/AIDS therapy sales forecasts to 2009

3 August 2000

Glaxo Wellcome's last independent results show company in good health

28 July 2000

BioChem Pharma earnings up 34%

3 May 2000

Glaxo Wellcome 1999 profits take a slight tumble, as sales rise just 5%

17 February 2000

Glaxo SmithKline, an R&D powerhouse and global number one - updated story

18 January 2000

Glaxo SmithKline, an R&D powerhouse and global number one

17 January 2000

BioChem Pharma profits up 17%

29 October 1999

Sustiva, Combivir "beat HIV non-compliance"

13 October 1999

Remune combo trial

27 September 1999

Sharp earnings rise at BioChem Pharma

2 August 1999

GW gains EU approval for Ziagen

13 July 1999

BioChem Pharma posts 39% revenue rise

5 May 1999

South Africa tells AIDS drugmakers:cut your prices

30 April 1999

Glaxo Wellcome expecting double-digit growth in sales and earnings for 1999

19 February 1999

US HIV conference data in brief

4 February 1999

Epivir boosts earnings at BioChem Pharma

3 February 1999

Low compliance could fuel AIDS epidemic

26 January 1999

Glaxo Wellcome's Ziagen launched for HIV in its first market, the USA -

7 January 1999

G-W's Ziagen approved in USA

21 December 1998

Canada Approve Combivir for HIV Infection

9 December 1998

GW's Ziagen Endorsed By FDA Committee

3 November 1998

First Approval Of DuPont's Sustiva In USA

21 September 1998

Review Of US Second Qtr & Implications For Euro Firms

20 August 1998

Healthy 2nd Qtr Sales/ Earnings At BioChem

5 August 1998

Strong Sterling Hits Glaxo Wellcome's 1st-Half Profits

30 July 1998

GW's Abacavir Combo As Potent As PI Regimen

30 June 1998

GW's Combivir OKed In EU

19 March 1998

Glaxo Wellcome Profits Hit By Strength Of Sterling

19 February 1998

B-MS' Zerit Overtakes Glaxo's Zidovudine

30 January 1998

EU Approval Granted For Combivir

4 December 1997

UK Approves GW's Combivir

27 November 1997

GW's Combivir Approved In The USA For HIV

1 October 1997

Showing 1-86 of 86 articles

Go to beginningPrevious
  • 1
NextGo to end